Form 8-K - Current report:
SEC Accession No. 0001664710-25-000055
Filing Date
2025-06-06
Accepted
2025-06-06 16:02:15
Documents
14
Period of Report
2025-06-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kros-20250606.htm   iXBRL 8-K 39813
2 EX-99.1 exhibit9916625pr.htm EX-99.1 6299
  Complete submission text file 0001664710-25-000055.txt   210741

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20250606.xsd EX-101.SCH 2166
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20250606_def.xml EX-101.DEF 17224
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20250606_lab.xml EX-101.LAB 28316
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20250606_pre.xml EX-101.PRE 17510
16 EXTRACTED XBRL INSTANCE DOCUMENT kros-20250606_htm.xml XML 4116
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 251030456
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)